BioSante Pharmaceuticals Presents CaP Nanotechnology Review at International Conference on Immunopotentiators in Modern Vaccines
LINCOLNSHIRE, Illinois (May 18, 2005) – BioSante Pharmaceuticals (AMEX: BPA) today announced that Dr. Steve Bell, vice president of research and pre-clinical development for BioSante, will present a review of progress with BioVant , the company’s patented calcium phosphate (CaP) nanoparticle technology, at the Second International Conference on Immunopotentiators in Modern Vaccines (IMV 2005) meeting in M˝laga, Spain. The presentation entitled, “Calcium Phosphate Nanoparticles versus Microparticles: Selective Th1 versus Th2 Immunity,” will take place Thursday, May 19 at 9:30 a.m. CEST (3:30 a.m. ET).
Dr. Bell will provide a review of progress toward the use of BioVant for “rational vaccine design.” Based upon careful analysis of immune response results in pre-clinical testing using BioVant in bacterial and viral vaccine candidates, the presentation will include a conceptualization of the functional efficacy of BioVant, which highlights its use to selectively elicit Th1 or Th2 T-helper immunity. This approach may lead to the ability to rapidly create highly specialized vaccines for emerging viruses and bioterrorism applications.
For more information on IMV 2005, please visit http://www.meetingsmanagement.com/imv_2005/.
Formulated using BioSante’s proprietary CaP nanotechnology, BioVant is being tested as an adjuvant for orally and intranasally administered anthrax vaccines, among other uses. While injectable aluminum salt (alum) derivatives are the only adjuvants currently approved by the FDA, they have been associated with adverse reactions including irritation and inflammation of the injection site. Composed of specially formulated calcium phosphate, BioVant has been shown not to cause inflammation or allergic reaction after administration. BioSante is developing BioVant under a subcontract with DynPort in support of the U.S. Department of Defense Joint Vaccine Acquisition Program (JVAP), among other collaborations.
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante’s lead products include Bio-E-Gel® (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel® (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at biosantepharma.cdmail.biz.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding BioSante contained in this press release that are not historical in nature, particularly those that utilize terminology such as “may,” “will,” “should,” “likely,” “expects,” “anticipates,” “estimates,” “believes” or “plans,” or comparable terminology, are forward-looking statements. Forward-looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements.
Important factors known to BioSante that cause actual results to differ materially from those expressed in such forward-looking statements are the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance, and other factors identified and discussed from time to time in BioSante’s filings with the Securities and Exchange Commission, including those factors discussed on pages 18 to 25 of BioSante’s Form 10-KSB, which discussion also is incorporated herein by reference.
For more information please contact:
Harris D. McKinney